Rapport Therapeutics is a clinical-stage biotech with strong analyst conviction at a price target implying 49% upside and a 3-for-4 earnings beat streak averaging 9.9% positive surprise, but the company burns cash at -247% of revenue, carries a quality score of 1.9 out of 10, and an extremely elevated put/call ratio of 4.36 signals heavy bearish options activity.
Thesis pillars
- High Analyst Conviction Upside↓Deteriorating
- Extreme Put Call Ratio↓Deteriorating
- Cash Burn Quality Floor Breach↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Rapport Therapeutics, Inc. (RAPP) Stock Analysis
Range Bound setup · Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $40.68: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 4.23; Below-average business quality; Negative price momentum.
Rapport Therapeutics is a clinical-stage biotech developing precision neuroscience medicines using its RAP technology platform, which targets receptor-associated proteins to achieve neuroanatomical specificity. Its lead candidate, RAP-219, an AMPA receptor modulator in-licensed... Read more
Sell if holding. Engine safety override at $40.68: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 4.23; Below-average business quality; Negative price momentum. Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 4.9/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: speculative.
About Rapport Therapeutics, Inc.
About Rapport Therapeutics, Inc.
Rapport Therapeutics' lead candidate, RAP-219, met its primary and secondary endpoints in a Phase 2a proof-of-concept trial reported in September 2025, showing a statistically significant reduction in both an objective seizure biomarker and clinical seizures in adults with drug-resistant focal onset seizures. Following supportive FDA feedback from an end-of-Phase-2 meeting in December 2025, the company expects to begin two Phase 3 trials of RAP-219 in the second quarter of 2026, targeting a $2.8 billion epilepsy market that is expected to grow to $3.6 billion by 2028.
Rapport has no approved products and generates no revenue; nearly all of its pipeline, including RAP-219 and its nicotinic acetylcholine receptor programs, was originally developed at Janssen Pharmaceutical and in-licensed under an August 2022 agreement that obligates Rapport to pay Janssen up to $76.0 million in development milestones and up to $40.0 million in sales milestones for RAP-219 products. Beyond RAP-219's focal-onset-seizure indication, the company is testing the same molecule in a Phase 2 proof-of-concept trial for bipolar mania, with topline data expected in the first half of 2027, and is developing a long-acting injectable formulation intended to improve adherence across all RAP-219 indications. Two earlier-stage discovery programs, RAP-641 for chronic pain and migraine and a program targeting the α9α10 receptor for hearing and vestibular disorders, round out the pipeline built on Rapport's receptor-associated-protein platform. Rapport reported net losses of $111.5 million in 2025 and $78.3 million in 2024.
Show full overview
Rapport's own risk factors state that its business is highly dependent on the success of its product candidates, particularly RAP-219 for focal onset seizures — a concentration sharpened by the fact that RAP-219 also carries the company's bipolar mania and planned PGTCS programs on the same molecule. A setback in the upcoming Phase 3 FOS trials, expected to start in the second quarter of 2026, would therefore not be contained to one indication: it would simultaneously cloud the bipolar mania readout expected in the first half of 2027 and the planned PGTCS Phase 3 start in the first half of 2027, since all three rely on the same TARP8-targeting mechanism.
See also: Healthcare · Biotechnology
From Rapport Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — Rapport Therapeutics, Inc.
Latest news
- NEWS BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target — benzinga Jul 16, 2026 positive
- NEWS Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52 — benzinga Jun 24, 2026 positive
- NEWS BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65 — benzinga May 21, 2026 positive
- NEWS Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56 — benzinga May 19, 2026 positive
- NEWS BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target — benzinga May 8, 2026 positive
Generated 2026-07-26T09:17:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineRAP-21910-K Item 1A: 'Our business is highly dependent on the success of our product candidates, particularly RAP-219 for FOS.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $40.68: Quality below floor (2.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 4.23; Below-average business quality; Negative price momentum. Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $37.83. Score 4.9/10, moderate confidence.
Take-profit target: $49.35 (+21.3% upside). Prior stop was $37.83. Stop-loss: $37.83.
Concentration risk — Pipeline: RAP-219; Quality below floor (2.3 < 4.0).
Rapport Therapeutics, Inc. trades at a P/E of N/A (forward -9.3). TrendMatrix value score: 7.5/10. Verdict: Sell.
18 analysts cover RAPP with a consensus score of 4.3/5. Average price target: $57.
What does Rapport Therapeutics, Inc. do?Rapport Therapeutics is a clinical-stage biotech developing precision neuroscience medicines using its RAP technology...
Rapport Therapeutics is a clinical-stage biotech developing precision neuroscience medicines using its RAP technology platform, which targets receptor-associated proteins to achieve neuroanatomical specificity. Its lead candidate, RAP-219, an AMPA receptor modulator in-licensed from Janssen, showed statistically significant seizure reduction in a Phase 2a trial for drug-resistant focal onset seizures reported in September 2025, with Phase 3 trials expected to begin in the second quarter of 2026.